Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rezolute (NASDAQ: RZLT) announced an inducement equity grant under Nasdaq Listing Rule 5635(c)(4) made as of September 30, 2025. The company granted options to purchase a total of 125,000 shares of common stock to two new employees.
The options carry a 10-year term, an exercise price of $9.40 per share (the closing price on September 30, 2025), and vest over four years subject to continued service. The awards were approved by the Compensation Committee as a material inducement to accept employment.
Rezolute (NASDAQ: RZLT) ha annunciato una Conferimento azioni di incentivo ai sensi della regola 5635(c)(4) di Nasdaq, effettuato al 30 settembre 2025. L'azienda ha assegnato opzioni per acquistare un totale di 125.000 azioni di azioni ordinarie a due nuovi dipendenti.
Le opzioni hanno una durata di 10 anni, un prezzo di esercizio di $9,40 per azione (il prezzo di chiusura al 30 settembre 2025) e maturano nell'arco di quattro anni soggetti al permanere del servizio. Le assegnazioni sono state approvate dal Compensation Committee come indizio sostanziale per accettare l'impiego.
Rezolute (NASDAQ: RZLT) anunció una concesión de acciones por inducción conforme a la Regla 5635(c)(4) de Nasdaq, con fecha de 30 de septiembre de 2025. La empresa otorgó opciones para comprar un total de 125,000 acciones de acciones comunes a dos nuevos empleados.
Las opciones tienen una vigencia de 10 años, un precio de ejercicio de $9,40 por acción (el precio de cierre el 30 de septiembre de 2025) y se consolidan/otorgan en un periodo de cuatro años sujeto a la continuación del servicio. Las adjudicaciones fueron aprobadas por el Comité de Compensación como un incentivo sustancial para aceptar el empleo.
Rezolute(나스닥: RZLT)은 나스닥 상장 규정 5635(c)(4)에 따른 유인 주식 부여를 2025년 9월 30일 기준으로 발표했습니다. 회사는 신규 두 명의 직원에게 총 125,000주의 보통주 매수 옵션을 부여했습니다.
옵션은 10년의 유효기간, 주당 행사가 $9.40의 행사가, 그리고 4년에 걸쳐 비탄력적 근속 조건으로 vesting됩니다. 보상 위원회는 고용 수락에 대한 중요한 인센티브로 이 보상을 승인했습니다.
Rezolute (NASDAQ : RZLT) a annoncé une attribution d’actions en tant qu’incitation conformément à la règle de cotation Nasdaq 5635(c)(4) en date du 30 septembre 2025. L’entreprise a accordé des options d’achat d’un total de 125 000 actions ordinaires à deux nouveaux employés.
Les options ont une durée de 10 ans, un prix d’exercice de 9,40 $ par action (le prix de clôture au 30 septembre 2025), et une acquisition qui vest sur quatre ans sous réserve de la poursuite du service. Les attributions ont été approuvées par le Comité de rémunération comme incitation substantielle à accepter l’emploi.
Rezolute (NASDAQ: RZLT) hat eine Induktionsaktienzuteilung gemäß Nasdaq Listing Rule 5635(c)(4) zum 30. September 2025 angekündigt. Das Unternehmen gewährte Optionen zum Kauf insgesamt 125.000 Stammaktien an zwei neue Mitarbeiter.
Die Optionen haben eine Laufzeit von 10 Jahren, einen Ausübungspreis von 9,40 USD pro Aktie (Schlusskurs am 30. September 2025) und vesten über vier Jahre bei fortgesetzter Anstellung. Die Zuteilungen wurden vom Vergütungsausschuss als wesentlicher Anreiz zur Annahme der Beschäftigung genehmigt.
Rezolute (NASDAQ: RZLT) أعلنت عن منح أسهم حافز وفقاً لقواعد إدراج ناسداك 5635(c)(4) كما في 30 سبتمبر 2025. منحت الشركة خيارات لشراء إجمالي 125,000 سهم من الأسهم العادية لاثنين من الموظفين الجدد.
تحمل الخيارات فترة صلاحية 10 سنوات، وسعر الإضراب $9.40 للسهم (سعر الإغلاق في 30 سبتمبر 2025)، وتكتمل خلال أربع سنوات رهناً بالاستمرار في الخدمة. تمت الموافقة على المنح من قبل لجنة التعويضات كحافز جوهري لقبول العمل.
Rezolute (NASDAQ: RZLT) 宣布了一项 引入性股权授予，根据纳斯达克上市规则5635(c)(4)，自 2025年9月30日 起生效。公司向两名新员工授予总计 125,000股普通股的期权。
这些期权的 任期为10年，行使价为每股 $9.40（2025年9月30日收盘价），并在 四年 内随职位的持续而逐步生效。该奖励已由薪酬委员会批准，作为接受雇佣的重大诱因。
- None.
- None.
REDWOOD CITY, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ: RZLT), (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that it has granted as of September 30, 2025 equity inducement awards to two new employees. The equity awards were approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees’ acceptance of employment with Rezolute.
The Company granted options to purchase 125,000 shares, in the aggregate, of Rezolute common stock to the new employees. The options have a 10-year term and an exercise price per share equal to
Forward-Looking Statements
This release, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in the Rezolute’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the SEC’s website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement.
Rezolute Contacts:
Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717
Carrie McKim
cmckim@rezolutebio.com
336-608-9706
FAQ
What did Rezolute (RZLT) grant on September 30, 2025?
What is the exercise price and term of the RZLT inducement options?
How do the RZLT inducement options vest?
Under which Nasdaq rule did Rezolute approve the inducement grant?
Who approved Rezolute's September 2025 equity inducement awards (RZLT)?
